NCT06212947 is a clinical trial in Hypochondroplasia, sponsored by BioMarin Pharmaceutical.

Who is sponsoring NCT06212947?

NCT06212947 is sponsored by BioMarin Pharmaceutical.

What condition does NCT06212947 study?

NCT06212947 studies Hypochondroplasia.

Is NCT06212947 still recruiting?

NCT06212947 is currently recruiting now. Last updated 3 April 2025.

Last reviewed 2025-04-03 · How we verify

NCT06212947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

Recruiting now Last updated 3 April 2025

What this trial tests

trial in Hypochondroplasia in 400 participants. Currently enrolling.

Timeline

27 November 2023

Primary endpoint
31 December 2043

31 December 2043

Quick facts

Lead sponsor	BioMarin Pharmaceutical
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	400
Start date	27 November 2023
Primary completion	31 December 2043
Estimated completion	31 December 2043
Sites	43 locations across France, Italy, Japan, United Kingdom, Germany, Argentina, Canada, Australia

Conditions studied

Hypochondroplasia — all drugs for Hypochondroplasia →

Sponsor

BioMarin Pharmaceutical — full company profile →

Who can join

Under 15, any sex, with Hypochondroplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypochondroplasia

Currently open trials in the same condition.

NCT07126262 — A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months · Phase 2 · recruiting
NCT06455059 — Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia · Phase 3 · active not recruiting
NCT05328050 — Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy) · recruiting

Other BioMarin Pharmaceutical trials

Trials by the same sponsor.

NCT07477691 — Immune Modulation During Palynziq® Treatment in Adults (IMPALA) · Phase 4 · not yet recruiting
NCT07126262 — A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months · Phase 2 · recruiting
NCT06309979 — A Study to Assess Growth in Children With Idiopathic Short Stature · recruiting
NCT06455059 — Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia · Phase 3 · active not recruiting
NCT06305234 — A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06212947 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioMarin Pharmaceutical
Last refreshed: 3 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06212947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing